What it Means to Demonstrate Target Engagement in Therapies that Target the Immune System: Role of Combination of Biomarkers.

Time: 2:00 pm
day: Day Two


  • Assessing target engagement of inflammatory treatments via multiple platforms and assays; why is it necessary?
  • “Anti-inflammatory” is not enough: Demonstrate downstream consequences of targeting inflammation
  • Integrating novel, non-invasive biomarkers, in early-stage trials – potential and limitations.